Table 1.

SIRT1 β-cell transgenics trend toward more diabetic incidence after MLDS, and SIRT1 +/− mice trend toward reduced diabetic incidence. Multiple low dose streptozotocin (MLDS) exposure (55 millig/kg i.p. on 5 consecutive days) was administered to mice (5–10 months of age) as indicated in a blinded fashion. Blood glucose was determined on Day 0, 1, 3, 7, 10, and 14 in a blinded fashion. Diabetic incidence was defined as blood glucose > 2.5 g/L. Mortality was recorded in a blinded fashion on the day that animals displayed akinesia after prodding, or inability to reach food.

Animal Condition	Diabetic Animals by 7 days	Diabetic Animals by 14 days	Surviving Animals by 21 days
Multiple Low Dose STZ in BESTO Tg-Ctrl	9 out of 20	12 out of 20	11 out of 20
Multiple Low Dose STZ in BESTO Tg+	11 out of 20	14 out of 20	8 out of 20
Multiple Low Dose STZ in SIRT1 +/+	9 out of 20	12 out of 20	11 out of 20
Multiple Low Dose STZ in SIRT1 +/−	6 out of 20*	9 out of 20*	13 out of 20*

^*indicates difference from BESTO Tg+ mice at P < 0.05 by student t-test.